Preclinical imaging

Boundless Bio Presents Preclinical Data on the Discovery of its Second ecDNA-Directed Therapeutic Candidate, BBI-825, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 13, 2023

BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.

Key Points: 
  • BBI-825 is a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), which is a rate-limiting enzyme in the cellular production of deoxynucleotide triphosphates (dNTPs), essential building blocks for ecDNA assembly and repair in cancer cells.
  • BBI-825 has demonstrated RNR inhibition in a host of tumor cell lines and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being evaluated in Investigational New Drug (IND)-enabling studies.
  • BBI-825 was discovered using Boundless Bio’s proprietary Spyglass platform, a drug discovery engine to identify and preclinically validate targets that are essential for cancer cells’ reliance on ecDNA for growth, treatment resistance, and survival.
  • Details of today’s presentations are as follows:
    Title: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRASG12C inhibitor in colorectal cancer (CRC)

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, August 23, 2023

In addition, Peak Bio’s lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.

Key Points: 
  • In addition, Peak Bio’s lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.
  • After some encouraging proof-of-concept (POC) data for Peak Bio’s proprietary ADC approach was presented at AACR 2021, the Company was motivated to explore a pipeline of potentially differentiated ADCs as investigational therapeutics in oncology.
  • Trop2 ADCs, conjugated with PH1 toxin at a drug-to-antibody (DAR) ratio of 4, demonstrated single digit nanomolar potency in eight different solid tumor indications.
  • A proprietary Trop2 PH1 ADC (antibody-linker-toxin), had equal or better on-target potency than first-in-class (FIC) Trop2 ADC.

Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines

Retrieved on: 
Thursday, May 25, 2023

Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines

Key Points: 
  • Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccines
    Preclinically validated for both DNA and mRNA vaccines, and ready for clinical testing
    Anticipated large market potential for DNA and mRNA vaccines against cancer, viral and bacterial diseases
    COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.
  • “We are excited to present this novel genetic adjuvant technology to the global scientific community.
  • It boosts Evaxion´s own DNA technology and has the potential to improve the effect of virtually any vaccine.
  • We foresee a great market potential in that this technology appears to be highly effective in both DNA and mRNA based vaccines against cancer as well as infectious diseases,” said Per Norlén, CEO at Evaxion.

Near Infrared Imaging Market Worth $2.81 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.
  • Moreover, growing incidences of chronic disorders, especially among the geriatric population, are fueling industry growth.
  • Read 102-page market research report, " Near Infrared Imaging Market Size, Share & Trends Analysis Report By Product (Devices, Reagents), By Application (Cancer Surgeries, Preclinical Imaging), By End-use (Hospitals & Clinics, Research Labs), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Growing applications of NIR in commercial operations & research activities in biopharmaceutical companies as well as academic institutes are expected to drive the demand for advanced NIR systems in the coming years...
    Grand View Research has segmented the global near infrared imaging market based on product, application, end-use, and region
    NIR Imaging Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Near Infrared Imaging Market Worth $2.81 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, January 19, 2023

SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Jan. 19, 2023 /PRNewswire/ -- The global near infrared imaging market size is expected to reach USD 2.81 billion by 2030, registering a CAGR of 4.0% from 2022 to 2030, according to a new report by Grand View Research, Inc.
  • Moreover, growing incidences of chronic disorders, especially among the geriatric population, are fueling industry growth.
  • Read 102-page market research report, " Near Infrared Imaging Market Size, Share & Trends Analysis Report By Product (Devices, Reagents), By Application (Cancer Surgeries, Preclinical Imaging), By End-use (Hospitals & Clinics, Research Labs), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Growing applications of NIR in commercial operations & research activities in biopharmaceutical companies as well as academic institutes are expected to drive the demand for advanced NIR systems in the coming years...
    Grand View Research has segmented the global near infrared imaging market based on product, application, end-use, and region
    NIR Imaging Market - Product Outlook (Revenue, USD Million, 2018 - 2030)

Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022

Imlunestrant was specifically designed to deliver continuous estrogen receptor target inhibition throughout the dosing period and regardless of ESR1 mutational status.

Key Points: 
  • Imlunestrant was specifically designed to deliver continuous estrogen receptor target inhibition throughout the dosing period and regardless of ESR1 mutational status.
  • Interested patients and physicians can contact the Loxo Oncology at Lilly clinical trial team by e-mailing [email protected] .
  • Across four clinical trials in 3691 patients, diarrhea occurred in 81 to 90% of patients who received Verzenio.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022

EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22.

Key Points: 
  • EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22.
  • Additionally, EXUMA presented robust B cell aplasia results obtained by directly injecting a CD3-targeting lentiviral vector (GCAR) into two different lymphoreplete humanized animal models.
  • Further pre-clinical studies are ongoing to characterize the pharmacokinetic and pharmacodynamic effects of EXUMA's GCAR gene therapy.
  • EXUMA Biotech is headquartered in West Palm Beach.For more information visit exumabio.com and connect with us on LinkedIn and Twitter .

EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, March 15, 2022

EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22.

Key Points: 
  • EXUMA is currently conducting IND-enabling studies of the first products on its CAR-TaNK cell therapy platform, targeting CD19 and CD22.
  • Additionally, EXUMA presented robust B cell aplasia results obtained by directly injecting a CD3-targeting lentiviral vector (GCAR) into two different lymphoreplete humanized animal models.
  • Further pre-clinical studies are ongoing to characterize the pharmacokinetic and pharmacodynamic effects of EXUMA's GCAR gene therapy.
  • EXUMA Biotech is headquartered in West Palm Beach.For more information visit exumabio.com and connect with us on LinkedIn and Twitter .

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

Retrieved on: 
Wednesday, January 5, 2022

CAMBRIDGE, Mass. and EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, and Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today announced a licensing and collaboration agreement for the development of an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases.

Key Points: 
  • In exchange, Intellia received an equity stake in Kyverna and made an additional investment in Kyverna.
  • Recognizing the favorable characteristics as highly desirable for the treatment of autoimmune diseases, Kyverna, through its collaboration with Intellia, plans to develop the construct in the CRISPR/Cas9-engineered allogeneic CD19 CAR T KYV-201 for use in B-cell mediated autoimmune diseases.
  • Intellias ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
  • Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.

Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

Retrieved on: 
Monday, January 3, 2022

Kyverna has obtained rights to use the construct in both autologous and allogeneic CAR T-cell therapies.

Key Points: 
  • Kyverna has obtained rights to use the construct in both autologous and allogeneic CAR T-cell therapies.
  • Kyverna intends to advance the autologous version of this novel CD19 construct, KYV-101, into clinical development for autoimmune diseases in the first half of 2022.
  • "KYV-101, with its differentiated safety profile, holds great promise to transform the care and outcomes for patients with B-cell-driven autoimmune diseases."
  • Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.